Could Cytosorbents Corporation (CTSO) Go Up? The Stock Formed Bullish Wedge Up Pattern

December 7, 2017 - By wolcottdaily

Investors sentiment decreased to 0.73 in Q2 2017. Its down 2.41, from 3.14 in 2017Q1. It fall, as 4 investors sold Cytosorbents Corporation shares while 11 reduced holdings. 3 funds opened positions while 8 raised stakes. 1.87 million shares or 55.22% less from 4.19 million shares in 2017Q1 were reported.
Geode Capital Ltd invested in 127,125 shares or 0% of the stock. Bank Of Ny Mellon invested in 0% or 25,519 shares. Northern holds 0% in Cytosorbents Corporation (NASDAQ:CTSO) or 36,840 shares. Salem Invest Counselors has 0.01% invested in Cytosorbents Corporation (NASDAQ:CTSO) for 13,000 shares. Vanguard Group Inc Inc holds 0% or 452,056 shares in its portfolio. 6,200 were accumulated by Creative Planning. Private Advisor Gru Llc owns 10,000 shares. Susquehanna Grp Limited Liability Partnership holds 0% or 73,834 shares. Aviance Management Ltd holds 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO) for 1,580 shares. Glenmede Na reported 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Manufacturers Life The reported 1,600 shares or 0% of all its holdings. Raymond James & Assocs holds 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO) for 50,000 shares. State Street Corp holds 0% or 12,000 shares in its portfolio. Skylands Cap Ltd Co reported 0.35% in Cytosorbents Corporation (NASDAQ:CTSO). Pnc Financial Gp Incorporated invested in 0% or 38,000 shares.

The stock of Cytosorbents Corporation (CTSO) formed an up wedge with $7.36 target or 9.00 % above today’s $6.75 share price. The 5 months wedge indicates low risk for the $193.67 million company. If the $7.36 price target is reached, the company will be worth $17.43M more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 0.37% or $0.03 during the last trading session, reaching $6.75. About 69,790 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has declined 4.26% since December 8, 2016 and is downtrending. It has underperformed by 20.96% the S&P500.

Analysts await Cytosorbents Corporation (NASDAQ:CTSO) to report earnings on March, 2. They expect $-0.12 earnings per share, up 25.00 % or $0.04 from last year’s $-0.16 per share. After $-0.07 actual earnings per share reported by Cytosorbents Corporation for the previous quarter, Wall Street now forecasts 71.43 % negative EPS growth.

Cytosorbents Corporation (NASDAQ:CTSO) Ratings Coverage

Among 7 analysts covering CytoSorbents (NASDAQ:CTSO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents had 12 analyst reports since October 29, 2015 according to SRatingsIntel. Maxim Group initiated it with “Buy” rating and $8 target in Tuesday, May 24 report. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, September 26 report. The rating was initiated by Aegis Capital on Wednesday, October 26 with “Buy”. The rating was maintained by Maxim Group with “Buy” on Wednesday, July 5. The company was maintained on Monday, July 17 by Maxim Group. WBB Securities upgraded the shares of CTSO in report on Thursday, October 29 to “Buy” rating. Aegis Capital maintained the stock with “Buy” rating in Tuesday, May 30 report. B. Riley & Co initiated Cytosorbents Corporation (NASDAQ:CTSO) rating on Friday, October 7. B. Riley & Co has “Buy” rating and $11.25 target. The rating was maintained by Maxim Group with “Buy” on Tuesday, August 8.

More notable recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Seekingalpha.com which released: “Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results – Earnings Call …” on November 10, 2017, also Seekingalpha.com with their article: “Cytosorbents: A Razor & Razor Blade Story” published on June 28, 2017, Prnewswire.com published: “CytoSorbents – A Leader in Blood Purification to Treat Deadly Inflammation …” on June 06, 2017. More interesting news about Cytosorbents Corporation (NASDAQ:CTSO) were released by: Prnewswire.com and their article: “Dr. Eric R. Mortensen, MD, Ph.D., Clinical Trial Veteran, Joins CytoSorbents …” published on May 30, 2017 as well as Seekingalpha.com‘s news article titled: “Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position” with publication date: August 04, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.